Public health; Oklahoma Rare Disease Advisory Council; purpose; appointment procedures; membership requirements; annual report; membership terms; vacancies; term; effective date.
HB1019 creates the Oklahoma Rare Disease Advisory Council within the State Department of Health. The council’s stated purpose is to advise the public, the Legislature, and state agencies on the needs of Oklahomans living with rare diseases, also referred to as orphan diseases. It is designed to gather public input, hold hearings, consult experts, and develop recommendations on diagnosis, treatment, access to specialists, insurance coverage, and related services.
The bill requires the council to include at least 17 members representing a broad mix of stakeholders, including state agencies, health care providers, patients, caregivers, researchers, insurers, and industry representatives. It sets appointment procedures, term lengths, vacancy-filling rules, and requires the council to meet at least quarterly, maintain a public website, and submit annual reports to legislative leaders and the Governor. The first meeting must occur by February 1, 2026, and the act would take effect November 1, 2025.
If enacted, HB1019 would add a new advisory body to Title 63 of the Oklahoma Statutes and create an ongoing state-level mechanism for studying and responding to rare disease issues. It would not directly change treatment rules or insurance mandates, but it would influence future policy by generating recommendations on health coverage, diagnostics, emergency planning, research, and health equity for rare disease patients and caregivers. The bill also imposes transparency and reporting requirements on the council and the Department of Health.
The available context shows no recorded committee debate or votes, so there is no documented opposition or support in the provided materials. Based on the bill text, the measure appears policy-oriented and collaborative, with an emphasis on public input, stakeholder representation, and expert consultation. Its structure suggests a generally favorable or at least exploratory approach to addressing rare disease needs rather than a controversial regulatory change.
No specific points of contention are documented in the provided transcripts or voting history. Potential areas that could draw scrutiny include the size and composition of the council, the inclusion of representatives from industry and insurers alongside patients and advocates, and the administrative burden of creating a new advisory body. Another possible issue is whether the council’s recommendations will lead to future costs or policy changes, but those concerns are not reflected in the available record.